Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease.

[1]  K. Lyons,et al.  Old Drugs, New Delivery Systems in Parkinson’s Disease , 2019, Drugs & Aging.

[2]  J. Cedarbaum,et al.  Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 , 2019, Movement disorders : official journal of the Movement Disorder Society.

[3]  J. Jankovic,et al.  Botulinum toxin for the treatment of tremor. , 2019, Parkinsonism & related disorders.

[4]  R. Pahwa,et al.  Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial , 2019, The Lancet Neurology.

[5]  A. Lang,et al.  Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease , 2019, The New England journal of medicine.

[6]  J. Jankovic.  Pathogenesis‐targeted therapeutic strategies in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[7]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[8]  J. Jankovic,et al.  Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial , 2018, JAMA neurology.

[9]  L. Vacca,et al.  Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy? , 2018, Expert opinion on pharmacotherapy.

[10]  C. Sampaio,et al.  International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[11]  M. Vidailhet,et al.  Longitudinal analysis of impulse control disorders in Parkinson disease , 2018, Neurology.

[12]  W. Poewe,et al.  Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features , 2018, Movement disorders : official journal of the Movement Disorder Society.

[13]  C. Tanner,et al.  ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial , 2017, JAMA neurology.

[14]  A. Lang,et al.  Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. , 2017, JAMA neurology.

[15]  Michael J Frank,et al.  Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update , 2017, The Lancet Neurology.

[16]  N. Iwata,et al.  Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis. , 2017, Journal of Alzheimer's disease : JAD.

[17]  Stanley Fahn,et al.  Levodopa therapy for Parkinson disease , 2016, Neurology.

[18]  Y Ben-Shlomo,et al.  Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[19]  Gilberto Fisone,et al.  Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease , 2015, Progress in Neurobiology.

[20]  J. Brotchie,et al.  Monoamine Reuptake Inhibitors in Parkinson's Disease , 2015, Parkinson's disease.

[21]  Susan H Fox,et al.  Clinical spectrum of levodopa‐induced complications , 2015, Movement disorders : official journal of the Movement Disorder Society.

[22]  U. Dillmann,et al.  Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. , 2014, Parkinsonism & related disorders.

[23]  PD Med Collaborative Group.  Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial , 2014, The Lancet.

[24]  Marianna Amboni,et al.  The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa , 2014, Brain : a journal of neurology.

[25]  J. Jankovic,et al.  Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. , 2014, Parkinsonism & related disorders.

[26]  A. Berardelli,et al.  Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease , 2013, European journal of neurology.

[27]  J. Jankovic,et al.  Emerging therapies for Parkinson's disease. , 2012, Current opinion in neurology.

[28]  S. Bruley des Varannes,et al.  Parkinson disease , 2011, Neurology.

[29]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes , 2011, The Lancet Neurology.

[30]  L. Descarries,et al.  Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia , 2010, Annals of neurology.

[31]  F. Grandas,et al.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review , 2009, Journal of Neural Transmission.

[32]  A. Lang,et al.  Non-dopaminergic treatments in development for Parkinson's disease , 2008, The Lancet Neurology.

[33]  A. Lees,et al.  Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD , 2008, Neurology.

[34]  G. Halliday,et al.  The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.

[35]  J. Ferreira,et al.  Dopamine agonist therapy in early Parkinson's disease. , 2008, The Cochrane database of systematic reviews.

[36]  Werner Poewe,et al.  Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.

[37]  W. Poewe,et al.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.

[38]  Werner Poewe,et al.  Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.

[39]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[40]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[41]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[42]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[43]  P. Leigh,et al.  Treatment of parkinsonism with bromocriptine. , 1974, Lancet.

[44]  R R Young,et al.  Amantadine in Parkinson's disease. Review of more than two years' experience. , 1972 .